Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 67Polycystic Ovary Syndrome 3Neoplasms, Hormone-Dependent 3Neoplasm Metastasis 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Breast Cancer Female 2Advanced Breast Cancer 2Sexuality 1Sexual Dysfunctions, Psychological 1Osteoporosis 1Luminal B/HER2-negative Breast Cancer 1Leiomyoma 1Infertility 1Hot Flashes 1Hormone Receptor Positive Breast Carcinoma 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Fractures, Bone 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1

Interventions

Acupuncture Therapy 10Gabapentin 6Venlafaxine Hydrochloride 4Isoflavones 3Estrogens, Conjugated (USP) 3Bupivacaine 3liposomal amphotericin B 2fezolinetant 2black cohosh root extract 2Tamoxifen 2Soybean Proteins 2Sodium Chloride 2Moxifloxacin 2Magnesium Oxide 2Hypnosis 2Control Groups 2Caspofungin 2zopiclone 1oxybutynin 1bazedoxifene 1Zolpidem 1Vitamin B 6 1Vancomycin 1Therapeutics 1Testosterone 1Tazobactam 1Tablets 1Sugars 1Solifenacin Succinate 1Progesterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hot Flashes × Aromatase Inhibitors × Clear all
NCT06440967 2026-04-06

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

Astellas Pharma Inc

Phase 3 Active not recruiting
984 enrolled

Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡